STOCK TITAN
  1. Home
  2. News
  3. CLRB

Cellectar Biosciences INC NEW - CLRB STOCK NEWS

Welcome to our dedicated page for Cellectar Biosciences NEW news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences NEW stock.

Cellectar Biosciences Inc. (symbol: CLRB) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs aimed at treating cancer. The company's core focus is leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which is designed to target cancer cells specifically, thereby enhancing efficacy and reducing off-target effects.

Cellectar's PDC platform is founded on proprietary phospholipid ether analogs, small molecules known for their selective uptake and retention in various cancers. This technology underpins the company's product pipeline, which includes both therapeutic and diagnostic agents for oncology. The lead therapeutic candidate, CLR 131, utilizes the cytotoxic radioisotope iodine-131 as its payload. CLR 131 has received orphan drug designation from the US FDA and is currently being evaluated in a Phase 1 clinical study for relapsed or refractory multiple myeloma and a Phase 2 clinical study for a range of B-cell malignancies.

In addition to CLR 131, Cellectar is working on developing proprietary PDCs for targeted chemotherapeutic delivery, with several candidates in preclinical stages. The company actively collaborates with research and development partners to expand its PDC platform's applications.

Financially, Cellectar maintains a robust pipeline and continues to secure funding for its clinical and preclinical programs. The company’s innovative approach and partnerships highlight its significant role in the biopharmaceutical landscape.

For more detailed and latest updates, please visit Cellectar’s official website or follow their social media channels.

News

Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Rhea-AI Summary
Cellectar Biosciences, a late-stage clinical biopharmaceutical company (NASDAQ: CLRB), announced a partnership with American Oncology Network (AON) and Meaningful Insights-BioTech Analytics (MiBA) to advance the treatment of Waldenstrom's macroglobulinemia (WM) in the community setting. Positive topline data from the pivotal Clover WaM study for iopofosine I 131 was reported, achieving a 61% major response rate (MRR) and exceeding the protocol statistical hurdle of 20%. The partnership aims to enrich the WM treatment paradigm and optimize outcomes with iopofosine I 131 upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
partnership
-
News

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia

Rhea-AI Summary
Cellectar Biosciences, a late-stage clinical biopharmaceutical company (NASDAQ: CLRB), announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia patients. The study met its primary endpoint with a major response rate (MRR) of 61% and an overall response rate (ORR) of 75.6%. The drug achieved a 100% disease control rate, with durable responses and a promising safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.08%
Tags
clinical trial
-
News

Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024

Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) to Host Conference Call and Present at Biotech Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
News

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announces exclusive license agreement with WARF for iopofosine I 131 in pediatric cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
News

Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform

Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has received expanded global patent protection for its Phospholipid Drug Conjugate™ (PDC) platform to deliver flavaglines as targeted anticancer payloads. The patent covers composition of matter and use protection for the PDC platform in combination with flavaglines in key global regions, including Japan, China, Eurasia, Brazil, and Mexico, following prior allowances in the US, Europe, Australia, and Canada. This expansion supports Cellectar's plan to develop a diverse product portfolio beyond radiotherapies, with a focus on reporting topline data for its lead radioconjugate therapy, iopofosine I 131, in January 2024, and expanding its pipeline of PDCs in high-need cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
News

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that its COO, Jarrod Longcor, will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe in Berlin, Germany. The presentation will focus on advancing universal targeted radiotherapies for solid and hematologic malignancies, highlighting the company's proprietary PLE delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
News

Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

Rhea-AI Summary
Cellectar Biosciences, Inc. reports preliminary financial results for Q3 2023, including $19.0 million in cash and cash equivalents. They closed a private placement financing with potential gross proceeds of up to $102.9 million. The company also received PRIME designation for iopofosine I 131 and expanded their intellectual property portfolio. They plan to release top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia (WM) during the JP Morgan Healthcare conference in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
News

Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting

Rhea-AI Summary
Cellectar Biosciences announced a partnership with Florida Cancer Specialists & Research Institute to advance patient care and define the treatment landscape for Waldenstrom's macroglobulinemia (WM) in the community oncology setting. The collaboration aims to evaluate unmet needs and optimize novel therapies for WM patients. Cellectar expects to release top-line data from its pivotal trial in 4Q 2023 and remains on target for a 2024 US product launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
partnership
-
News

Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023

Rhea-AI Summary
Cellectar Biosciences to report Q3 2023 financial results on November 2 and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
earnings
News

Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

Rhea-AI Summary
Cellectar Biosciences appoints William Yoon as VP of Medical Affairs and Aaditya Nanduri as VP of Business Strategy and Analytics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
management

FAQ

What is the current stock price of Cellectar Biosciences NEW (CLRB)?

The current stock price of Cellectar Biosciences NEW (CLRB) is $0.3454 as of January 3, 2025.

What is the market cap of Cellectar Biosciences NEW (CLRB)?

The market cap of Cellectar Biosciences NEW (CLRB) is approximately 13.0M.

What is Cellectar Biosciences' primary focus?

Cellectar Biosciences focuses on developing drugs for cancer treatment using their proprietary Phospholipid Drug Conjugate (PDC) delivery platform.

What is the lead therapeutic candidate of Cellectar Biosciences?

The lead therapeutic candidate is CLR 131, a PDC that uses iodine-131 to target and kill cancer cells.

What are the current clinical trials for CLR 131?

CLR 131 is undergoing a Phase 1 clinical study for relapsed or refractory multiple myeloma and a Phase 2 study for various B-cell malignancies.

Has CLR 131 received any designations from the FDA?

Yes, CLR 131 has been designated as an orphan drug by the US FDA.

What is the proprietary technology behind Cellectar's PDC platform?

The PDC platform is based on proprietary phospholipid ether analogs that selectively uptake and retain in cancer cells.

Is Cellectar Biosciences involved in any partnerships?

Yes, the company collaborates with research and development partners to expand the applications of its PDC platform.

What other products are under development at Cellectar?

Cellectar is developing additional PDCs for targeted chemotherapeutic delivery, with several in preclinical stages.

Where can I find more information about Cellectar Biosciences?

For more information, visit the official Cellectar Biosciences website or follow their social media channels.

How does Cellectar's PDC platform improve cancer treatment?

The PDC platform targets cancer cells specifically, enhancing treatment efficacy and reducing off-target effects.

What makes Cellectar Biosciences significant in the biopharmaceutical field?

Cellectar's innovative targeted delivery platform and its robust clinical pipeline highlight its significant role in advancing cancer treatment.
Stock CLRB logo
Cellectar Biosciences INC NEW

Nasdaq:CLRB

CLRB Rankings

#5555 Ranked by Market Cap
N/A Ranked by Dividends

CLRB Stock Data

12.99M
37.66M
2.84%
34.55%
4.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FLORHAM PARK